TRCT
NMRA icon

Tower Research Capital (TRC)’s Neumora Therapeutics NMRA Stock Holding History

Tower Research Capital (TRC)’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Buy
9,763
+5,695
+140% +$10.8K ﹤0.01% 3705
2026
Q1 		$7.93K Sell
4,068
-13,651
-77% -$35.4K ﹤0.01% 3995
2025
Q4 		$31.7K Sell
17,719
-3,262
-16% -$7.14K ﹤0.01% 2770
2025
Q3 		$38.2K Sell
20,981
-2,246
-10% -$3.63K ﹤0.01% 2737
2025
Q2 		$17K Buy
23,227
+3,316
+17% +$2.51K ﹤0.01% 3764
2025
Q1 		$19.9K Buy
19,911
+18,593
+1,411% +$31.8K ﹤0.01% 2978
2024
Q4 		$14K Sell
1,318
-3,624
-73% -$43.4K ﹤0.01% 3489
2024
Q3 		$65.3K Buy
4,942
+1,256
+34% +$14.7K ﹤0.01% 2566
2024
Q2 		$36.2K Buy
3,686
+1,050
+40% +$10.9K ﹤0.01% 3348
2024
Q1 		$36.2K Buy
2,636
+78
+3% +$1.26K ﹤0.01% 2493
2023
Q4 		$43.6K Buy
+2,558
New +$31.4K ﹤0.01% 3220

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Tower Research Capital (TRC)'s NMRA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Neumora Therapeutics (NMRA) stake by 140% in Q2 2026, buying an estimated $10.8K and bringing the position to 9,763 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3705.

Tower Research Capital (TRC) first reported a position in NMRA in Q4 2023 and has held it in 11 quarters since. The position peaked at $65.3K in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Tower Research Capital (TRC) held 9,763 shares of Neumora Therapeutics worth $16.6K as of Q2 2026.
  • Tower Research Capital (TRC) bought 5,695 Neumora Therapeutics shares in Q2 2026, an estimated $10.8K.
  • Neumora Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3705 holding.
  • Tower Research Capital (TRC) first reported a position in Neumora Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Tower Research Capital (TRC)'s Neumora Therapeutics position peaked at $65.3K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.